Cargando…

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection

We have previously demonstrated an impact of the BRAF inhibitor vemurafenib on patient lymphocyte counts. In the current study, the extent to which concomitant use of corticosteroids in BRAF inhibitor treated patients affects lymphocyte counts and predisposes to infection was investigated. A cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sondermann, Wiebke, Griewank, Klaus G., Schilling, Bastian, Livingstone, Elisabeth, Leyh, Julia C., Rompoti, Natalia, Cosgarea, Ioana, Schimming, Tobias, Schadendorf, Dirk, Zimmer, Lisa, Hillen, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405567/ https://www.ncbi.nlm.nih.gov/pubmed/25897843 http://dx.doi.org/10.1371/journal.pone.0124590

Ejemplares similares

TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma
por: Griewank, Klaus G., et al.
Publicado: (2013)

Lack of SF3B1 R625 mutations in cutaneous melanoma
por: Schilling, Bastian, et al.
Publicado: (2013)

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Analysis of SDHD promoter mutations in various types of melanoma
por: Scholz, Simone L., et al.
Publicado: (2015)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
por: Żołek, Teresa, et al.
Publicado: (2023)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

NF1 mutations in conjunctival melanoma
por: Scholz, S. L., et al.
Publicado: (2018)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
por: Chan, Sze Wai, et al.
Publicado: (2015)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis
por: Sondermann, Wiebke, et al.
Publicado: (2016)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
por: Shelledy, Lindsay, et al.
Publicado: (2015)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas
por: Gouravan, Sarina, et al.
Publicado: (2018)

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
por: Broudic-Guibert, Morgane, et al.
Publicado: (2019)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019)

VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer
por: Chen, Shitu, et al.
Publicado: (2020)

Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor
por: Chik, Constance L, et al.
Publicado: (2021)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
por: Guzzetti, Carlotta, et al.
Publicado: (2023)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
por: Kopetz, Scott, et al.
Publicado: (2015)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib
por: Nisiewicz, Monika K., et al.
Publicado: (2021)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Deep Penetrating Nevus and Borderline-Deep Penetrating Nevus: A Literature Review
por: Cosgarea, Ioana, et al.
Publicado: (2020)

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
por: Griewank, K G, et al.
Publicado: (2013)

COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates
por: Lodde, Georg C., et al.
Publicado: (2022)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_27iu7jrthofdqas7kucs7tppci